TP53 and colorectal carcinoma: A network pharmacology research shows that the main targets of HDW therapy for CRC are AKT, PIK, TP53, BRAF, CDK2, and RAF, Gene Ontology (GO) analysis suggested that HDW may exert anticancer activity through regulating tumor-related pathways, cell motility and cell community, which is consistent with the main molecular mechanisms reviewed in this article (Liu X et al., 2018).